BEDMINSTER, NJ, and DUBLIN, IRELAND - (ACCESSWIRE - October 15, 2013) - Amarin Corporation plc (AMRN) will host a live webcast to discuss the results of the U.S. Food and Drug Administration (FDA) advisory committee meeting, as well as the ANCHOR Advisory Committee Results, to be held Wednesday, October 16, 2013, at 7:00 p.m. Eastern Time.
To participate in this event, dial 877-407-8033 domestically, or 201-689-8033 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at http://www.investorcalendar.com/IC/CEPage.asp?ID=171519.
If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=171519 or http://www.investorcalendar.com/, as well as via the investor relations section of the Amarin Corporation plc web site (http://www.amarincorp.com/). A podcast of the event will also be available.
About Amarin Corporation plc
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa(R) (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit http://www.vascepa.com/. For more information about Amarin visit http://www.amarincorp.com/.
- Health Care Industry